1. Home
  2. BLTE vs G Comparison

BLTE vs G Comparison

Compare BLTE & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$158.49

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Logo Genpact Limited

G

Genpact Limited

HOLD

Current Price

$34.56

Market Cap

5.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLTE
G
Founded
2018
1997
Country
United States
Bermuda
Employees
N/A
140000
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.8B
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
BLTE
G
Price
$158.49
$34.56
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
$198.00
$49.50
AVG Volume (30 Days)
117.4K
2.4M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
2.21%
EPS Growth
N/A
9.82
EPS
N/A
3.13
Revenue
N/A
$2,279,438,000.00
Revenue This Year
N/A
$9.20
Revenue Next Year
$492.11
$7.27
P/E Ratio
N/A
$10.83
Revenue Growth
N/A
N/A
52 Week Low
$56.68
$33.53
52 Week High
$200.00
$50.24

Technical Indicators

Market Signals
Indicator
BLTE
G
Relative Strength Index (RSI) 43.63 38.70
Support Level $157.63 $34.36
Resistance Level $161.28 $38.03
Average True Range (ATR) 6.26 1.04
MACD -1.15 -0.11
Stochastic Oscillator 17.27 29.40

Price Performance

Historical Comparison
BLTE
G

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About G Genpact Limited

Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.

Share on Social Networks: